Illumina (ILMN) Stock Rating Upgraded by BidaskClub
BidaskClub upgraded shares of Illumina (NASDAQ:ILMN) from a hold rating to a buy rating in a research report report published on Saturday morning.
Several other equities research analysts have also recently weighed in on the company. Wells Fargo & Co raised Illumina from a market perform rating to an outperform rating and set a $205.00 price target on the stock in a research note on Tuesday, January 2nd. Morgan Stanley upped their price target on Illumina from $122.00 to $135.00 and gave the stock an underweight rating in a research note on Thursday, December 14th. Zacks Investment Research raised Illumina from a hold rating to a buy rating and set a $252.00 price target on the stock in a research note on Tuesday, December 5th. Piper Jaffray Companies reaffirmed a buy rating and issued a $269.00 price target on shares of Illumina in a research note on Tuesday, January 9th. Finally, BTIG Research reaffirmed a hold rating on shares of Illumina in a research note on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $241.39.
Shares of Illumina (NASDAQ ILMN) opened at $253.54 on Friday. The firm has a market capitalization of $37,270.00, a price-to-earnings ratio of 42.68, a P/E/G ratio of 3.31 and a beta of 0.93. Illumina has a 12 month low of $158.02 and a 12 month high of $256.05. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.43.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $215.48, for a total value of $4,309,600.00. Following the sale, the director now directly owns 480,476 shares of the company’s stock, valued at $103,532,968.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Frances Arnold sold 250 shares of the company’s stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $241.50, for a total value of $60,375.00. Following the transaction, the director now directly owns 10,439 shares in the company, valued at $2,521,018.50. The disclosure for this sale can be found here. Insiders sold 72,887 shares of company stock worth $16,510,025 over the last three months. Corporate insiders own 0.89% of the company’s stock.
Several large investors have recently made changes to their positions in ILMN. Jackson Square Partners LLC lifted its holdings in shares of Illumina by 263.0% during the fourth quarter. Jackson Square Partners LLC now owns 1,034,454 shares of the life sciences company’s stock valued at $226,017,000 after purchasing an additional 749,468 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Illumina by 8.8% during the fourth quarter. Jennison Associates LLC now owns 4,412,621 shares of the life sciences company’s stock valued at $964,114,000 after purchasing an additional 355,200 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Illumina by 371.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 212,160 shares of the life sciences company’s stock valued at $46,355,000 after purchasing an additional 167,206 shares in the last quarter. Carillon Tower Advisers Inc. bought a new position in shares of Illumina during the fourth quarter valued at $33,752,000. Finally, Guggenheim Capital LLC lifted its holdings in shares of Illumina by 41.5% during the fourth quarter. Guggenheim Capital LLC now owns 421,361 shares of the life sciences company’s stock valued at $92,065,000 after purchasing an additional 123,555 shares in the last quarter. 91.51% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.thecerbatgem.com/2018/03/14/illumina-ilmn-stock-rating-upgraded-by-bidaskclub.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.